Abstract:Although the advent of checkpoint inhibitors has completely transformed both oncology practice and the way we think about the immune system in cancer, their underlying mechanisms of action are only now starting to become clear. Recently, there has been increasing interest in the combination of antibodies blocking two co-inhibitory receptors on T cells, PD-1 and TIGIT, with randomized phase II results in non-small cell lung cancer having yielded significant overall survival benefit. We have investigated the mechanistic rationale for this combination and found that the inhibition of both co-inhibitory receptors is required to most effectively re-activate the two co-stimulatory receptors controlled by PD-1 (CD28) and TIGIT (CD226). Indeed, both co-stimulatory receptors serve as clients of PD-1 which recruits cytosolic phosphatases (eg SHP2) to inactivate the ITAM motifs in both CD28 and CD226. TIGIT acts to inhibit CD226 function in T cells solely by outcompeting it for ligand (CD155/PVR) binding. Unexpectedly, preclinical studies have demonstrated that ligand blocking antibodies to TIGIT are most effective when they contain a functional Fc domain. This observation suggests that at some level, Fc receptor-bearing cells play a role in mediating the function of anti-TIGIT blockade. Although this may reflect a modulation of T regulatory cell or NK cell function, both of which are TIGIT-positive, there are several observations that implicate the involvement of myeloid cells, namely macrophages and dendritic cells. One such observation is the fact that in the case of PD-1 blockade, the most relevant pool of PD-L1 turns out to be expressed by dendritic cells: in mice, genetic elimination of PD-L1 expression by tumor cells or macrophages exerts little effect on tumor growth, whilst PD-L1 elimination from dendritic cells greatly enhances endogenous anti-tumor immunity (Oh et al., 2020, Nature Cancer). This result further suggests, as is now becoming more widely accepted, that PD-L1/PD-1 blockade primarily acts by enhancing the activation of tumor-specific T cells during antigen presentation by dendritic cells, rather than by the rejuvenation of exhausted intratumoral T cells. Given the client relationship between PD-1 and CD28/CD226, it seems reasonable that TIGIT blockade similarly works at the level of antigen-presenting myeloid cells, either dendritic cells or macrophages. In the case of TIGIT, the requirement for an intact Fc domain further implies that T cell-bound anti-TIGIT may work as an opsonin that concomitantly triggers Fcγ receptor signaling to alter the functional status of the myeloid compartment. Thus, not only is there a convergence between the PD-1 and TIGIT pathways, but also a convergence between T cells and myeloid cells that may be essential for the function of these regulatory pathways and for the therapeutic effect associated with their blockade. Citation Format: Ira Mellman. A convergence of myeloid cells and T cells controls cancer immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr SY19-02.

Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

TIGIT as an emerging immune checkpoint

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT

Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody

TIGIT in cancer immunotherapy

A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Abstract SY19-02: A convergence of myeloid cells and T cells controls cancer immunity

TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

TIGIT, a novel immune checkpoint therapy for melanoma

Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma